| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.9 | 0.8 |
| Net income | -29.0 | -15.1 |
| EPS (diluted, $ a share) | $-0.37 | $-0.55 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +138.9% |
|---|
10-Q filed with the SEC, NASDAQ: CAMP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Camp4 Therapeutics Corp: key numbers
- Share price
- $3.86Close, Nov 16
- Market cap
- $242M
- Shares outstanding
- 62.75MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Camp4 Therapeutics Corp
All →Camp4 Therapeutics Financial Results
CAMP4 Therapeutics reported third quarter 2026 financial results, ending the period with $124.5 million in cash and cash equivalents. The company received regulatory clearances in the UK and EU to expand its Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder and remains on track to dose the first patient by year-end 2026. Management expects its current cash runway to fund operations through the end of 2028.
“The third quarter was one of continued execution for CAMP4. With regulatory clearances now in place in Australia, Argentina, the United Kingdom, and the European Union, we have launched our first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder.”
Josh Mandel-Brehm, President and Chief Executive Officer
“There are no approved disease-modifying treatments for SYNGAP1, and we are committed to rapidly advancing the development of CMP-002 globally in the hopes of offering SYNGAP1 patients and families a potentially transformative solution that could one day dramatically improve their lives.”
Josh Mandel-Brehm, President and Chief Executive Officer
Camp4 Therapeutics Investor Presentation
CAMP4 Therapeutics held an Analyst Day meeting to present details on its planned Phase 1/2 ASCEND clinical trial of CMP-002 for SYNGAP1-related disorder. The company provided a comprehensive data presentation and updated its corporate pipeline overview, detailing the trial's design, inclusion criteria, and therapeutic dosing expectations.